Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients

• Published in: Antimicrobial agents and chemotherapy 2022-11, Vol.66 (11), p.e0032122
• Main Authors: Truong, Anh Quan, Dao, Xuan Co, Vu, Dinh Hoa, Nguyen, Hoang Anh, Do, Thi Hong Gam, Tran, Nhan Thang, Tran, Nhat Minh, Vu, Ngan Binh, Pham, Hong Nhung, Bui, Van Cuong, Trinh, The Anh, Dang, Quoc Tuan, Nguyen, Gia Binh, Lipman, Jeffrey, Cotta, Menino O, Roberts, Jason A
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antimicrobial Chemotherapy; Clinical Therapeutics; Critical Illness; Humans; Klebsiella pneumoniae; Meropenem - pharmacokinetics; Microbial Sensitivity Tests; Monte Carlo Method
• ISSN: 0066-4804; 1098-6596
• DOI: 10.1128/aac.00321-22

Critically ill patients are characterized by substantial pathophysiological changes that alter the pharmacokinetics (PK) of hydrophilic antibiotics, including carbapenems. Meropenem is a key antibiotic for multidrug-resistant Gram-negative bacilli, and such pathophysiological alterations can worsen treatment outcomes. This study aimed to determine the population PK of meropenem and to propose optimized dosing regimens for the treatment of multidrug-resistant Klebsiella pneumoniae in critically ill patients. Two plasma samples were collected from eligible patients over a dosing interval. Nonparametric population PK modeling was performed using Pmetrics. Monte Carlo simulations were applied to different dosing regimens to determine the probability of target attainment and the cumulative fraction of response, taking into account the local MIC distribution for K. pneumoniae. The targets of 40% and 100% for the fraction of time that free drug concentrations remained above the MIC (ƒT>MIC) were tested, as suggested for critically ill patients. A one-compartment PK model using data from 27 patients showed high interindividual variability. Significant PK covariates were the 8-h creatinine clearance for meropenem and the presence of an indwelling catheter for pleural, abdominal, or cerebrospinal fluid drainage for the meropenem volume of distribution. The target 100% ƒT>MIC for K. pneumoniae, with a MIC of ≤2 mg/liter, could be attained by the use of a continuous infusion of 2.0 g/day. Meropenem therapy in critically ill patients could be optimized for K. pneumoniae isolates with an MIC of ≤2 mg/liter by using a continuous infusion in settings with more than 50% isolates have a MIC of ≥32mg/L.